Sidoti Estimates Prenetics Global’s Q3 Earnings (NASDAQ:PRE)

Prenetics Global Limited (NASDAQ:PRE) – Sidoti cut their Q3 2027 earnings per share estimates for Prenetics Global in a report issued on Friday, February 20th. Sidoti analyst A. Hantman now forecasts that the company will post earnings of $0.71 per share for the quarter, down from their prior forecast of $0.76. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2027 earnings at $1.19 EPS and FY2027 earnings at $1.65 EPS.

Several other research analysts have also weighed in on PRE. Roth Mkm initiated coverage on shares of Prenetics Global in a research report on Wednesday, February 11th. They set a “buy” rating and a $36.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Cantor Fitzgerald raised their price objective on Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen cut Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Prenetics Global currently has a consensus rating of “Hold” and an average price target of $34.00.

Prenetics Global Stock Up 1.9%

Shares of PRE opened at $15.90 on Monday. Prenetics Global has a 52-week low of $3.09 and a 52-week high of $22.86. The company has a 50-day simple moving average of $17.81 and a 200-day simple moving average of $14.18. The company has a market capitalization of $267.60 million, a PE ratio of -3.96 and a beta of 0.35.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.22. The firm had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $36.15 million. Prenetics Global had a negative return on equity of 19.07% and a negative net margin of 61.33%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Quadrature Capital Ltd purchased a new position in Prenetics Global in the 4th quarter valued at about $468,000. Millennium Management LLC acquired a new position in shares of Prenetics Global in the fourth quarter valued at approximately $810,000. Manatuck Hill Partners LLC acquired a new position in shares of Prenetics Global in the fourth quarter valued at approximately $170,000. Boothbay Fund Management LLC purchased a new position in shares of Prenetics Global during the fourth quarter valued at approximately $241,000. Finally, 683 Capital Management LLC acquired a new stake in Prenetics Global during the fourth quarter worth approximately $1,181,000. Institutional investors and hedge funds own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.